In brief: Eqitx, Stirling Products
Monday, 12 July, 2004
Two Perth-based biotechs have made key executive appointments.
Drug development company Eqitx (ASX:EQX) has former CSL and Amrad business development executive Joy Hewitt as its chief commercialisation officer.
At CSL, Hewitt was R&D and pharmaceuticals business development manager, where her responsibilities included commercialising CSL projects, evaluating and securing R&D opportunities, and in-licensing pharmaceutical products for domestic and NZ markets. Eqitx said Hewitt had also acted as a consultant to Australian research, biotech and medical organisations.
Animal growth promoter specialist Stirling Products (ASX:STI) has appointed Murray Ward, a stockbroker with 20 years' experience, as an executive director.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
